• About
• Links
• Contact
• Sitemap
• 

Immunomodulators in Cancer Therapy: Emerging Products and Markets

This Kalorama Information report focuses on current and emerging immunomodulators for cancer. The report covers both current and emerging cancer immunomodulators in detail.

The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. These include bladder, breast, colorectal, head/neck, kidney, lung, ovarian, pancreatic, and prostate cancers, as well as leukemia, lymphoma, melanoma, multiple myeloma, and neuroblastoma.

The current market segment provides an overview, descriptions of products on the market, market estimates and forecasts, and competitive analysis of leading providers. The emerging market segment provides an overview, descriptions of products in development, market forecasts, and forecasted competitive analysis for 2008. The report also includes current issues and trends affecting the industry.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2003. Historical data was provided for the years 2001 and 2002, with forecast data provided for 2004 through 2008. Compound annual growth rates (CAGRs) are provided for the 2001-2003, 2003-2008 and 2001-2008 periods for each industry segment covered. Competitive analysis is provided for the year 2003 for the current market and projected competitive analysis for 2008 for the emerging market. The projected competitive analysis for 2008 was based on products in late stage development, probability of approval and marketing, and demographic trends.

Table of Contents

Chapter One: Executive Summary

• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

Chapter Two: Introduction

• History and Growth of the Cancer Treatment Market
  
  • Traditional Treatment
  • Immunomodulator Discovery
• Immuonologic Approaches to Cancer
• Demographics and Statistics

Chapter Three: Current Immunomodulators Available for Cancer Treatment

• Cancers with Available Products
  
  • Kidney Cancer
  • Leukemia
  • Lymphoma
  • Melanoma
• Description of Products
  
  • Interleukins
  • Interferons
  • Tumor Necrosis Factor
  • Growth Factors
• Market Size and Growth
• Competitive Analysis
  chapter Four: Emerging Immunomodulators for Cancer Treatment
  
  • Cancers with New Product Opportunities
    
    • Bladder Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Head and Neck
    • Kidney
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Multiple Myeloma
    • Neuroblastoma
    • Ovarian Cancer
    • Pancreas
    • Prostate Cancer
  • Cancer Immunomodulator Pipeline
    
    • Phase III
    • Phase II
    • Phase I
    • Preclinical
  • Market and Product Launch Forecasts
  • Potential Competitors and Analysis, 2008

Chapter Five: Issues and Trends

• Insurance and Reimbursement Issues
• Alliances Acquisitions and Licensing Agreements
• Marketing and Distribution Trends
• Immunogenicity
• Future Business Strategies
• PhytoImmunotherapy
• Thalidomide Controversy

Chapter Six: Total Market Size and Forecast

• Overview
• Total Market Size and Forecast
• Competitive Analysis

chapter Seven: Corporate Profiles of Current Developers

• Introduction
• Amgen, Inc.
• Berlex Laboratories/Schering AG
• Chiron Corporation
• Chugai Pharmaceutical Company, Ltd.
• Millennium Pharmaceuticals, Inc.
• OrthoBiotech Products, L.P.
• Roche
• Sankyo Company, Ltd.
• Schering-Plough Corporation

chapter Eight: Corporate Profiles of Emerging Developers

• Introduction
• Celgene Corporation
• CEL-SCI Corporation
• Coley Pharmaceutical Group
• EMD Lexigen
• Enzon Pharmaceuticals, Inc.
• Human Genome Sciences, Inc.
• IDM, SA
• Lorus Therapeutics Inc.
• Maxim Pharmaceuticals
• NeoPharm, Inc.
• Neurocrine Biosciences, Inc.
• Onyx Pharmaceuticals, Inc.
• Peregrine Pharmaceuticals, Inc.
• Xcyte Therapies, Inc.
• ZYCOS, Inc.

Appendix a: Regulatory Authorities and Research Organizations
Appendix b: Company Directory

 

list of exhibits

Chapter One: Executive Summary

• Table 1-1: The Total Market for Cancer Immunomodulators 2001-2008
• Figure 1-1: The Total Market for Cancer Immunomodulators 2001-2008

Chapter Two: Introduction

• Table 2-1: Estimated and Projected World Cancer Incidence by Common Type of Cancer, 2003 and 2020
• Figure 2-1: Estimated and Projected World Cancer Incidence by CommonType of Cancer, 2003 and 2020
• Table 2-2: Estimated and Projected World Cancer Mortality by CommonType of Cancer, 2003 and 2020
• Figure 2-2: Estimated and Projected World Cancer Mortality by CommonType of Cancer, 2003 and 2020
• Table 2-3: World Population by Selected Geographical Region, 2003-2050
• Figure 2-3: World Population by Selected Geographical Region, 2003-2050
• Table 2-4: Estimated World Population by Age and GeographicalRegion, 2003
• Figure 2-4: Estimated World Population by Age and GeographicalRegion, 2003
• Table 2-5: Life Expectancy at Birth by Selected Countries, 2000
• Table 2-6: United States Life Expectancy at Birth, 1990-2000, andProjections, 2005-2010
• Figure 2-5: United States Average Years of Life Lost Per Person Dying ofCancer, All Races, Both Sexes, 2000
• Figure 2-6: United States Estimated Person-Years of Life Lost Due toCancer, All Races, Both Sexes, 2000

Chapter Three: Current Immunomodulators Available for Cancer Treatment

• Table 3-1: Types of Leukemia
• Table 3-2: Classification of Non-Hodgkin’s Lymphomas
• Table 3-3: Malignant Conditions of the Skin
• Table 3-4: Estimated World and U.S. Incidence and Mortality of Cancers with Current Immunomodulator Treatments (thousands)
• Figure 3-1: Estimated World Incidence and Mortality of Cancers with Current Immunomodulator Treatment Available
• Figure 3-2: Estimated U.S. Incidence and Mortality of Cancers with Current Immunomodulator Treatment Available
• Table 3-5: Current Cancer Immunomodulator Market, 2001-2008(in millions of dollars at the manufacturers level)
• Figure 3-3: Current Cancer Immunomodulator Market, 2001-2008
• Table 3-6: Current Cancer Immunomodulator Market Revenues by TreatmentType, Tumor vs Adjunct, 2003
• Table 3-7: Current Cancer Immunomodulator Market Leading SuppliersShares by Market Revenues, 2003
• Figure 3-4: Current Cancer Immunomodulator Market Leading SuppliersMarket Share, 2003
• Table 3-8: Current Cancer Immunomodulator Market Leading SuppliersShares by Market Revenues, Estimated 2004
• Figure 3-5: Current Cancer Immunomodulator Market Leading SuppliersMarket Share, Estimated 2004

chapter Four: Emerging Immunomodulators for Cancer Treatment

• Table 4-1: Types of Leukemia
• Table 4-2: Types of Primary Lung Cancer
• Table 4-3: Classification of Non-Hodgkin’s Lymphomas
• Table 4-4: Malignant Conditions of the Skin
• Table 4-5: Estimated World Incidence and Mortality of Cancers with Potential Immunomodulators in Development (in thousands)
• Figure 4-1: Estimated World Incidence and Mortality of Cancers with Emerging Immunomodulator Treatments
• Figure 4-2: Estimated U.S. Incidence and Mortality of Cancers with Emerging Immunomodulator Treatments
• Table 4-6: Cancer Immunomodulators in the Pipeline
• Table 4-7: Emerging Cancer Immunomodulators Market 2004-2008
• Figure 4-3: Emerging Cancer Immunomodulators Market, 2004-2008
• Table 4-8: Emerging Cancer Immunomodulators Market by CancerType 2004-2008
• Figure 4-4: Emerging Cancer Immunomodulators Market by TypeRevenues and Percent Distribution, 2004-2008
• Table 4-10: Emerging Cancer Immunomodulators Market ProjectedRevenues and Market Shares of Leading Developers 2008
• Figure 4-6: Emerging Cancer Immunomodulators Market Projected MarketShares of Leading Developers 2008

Chapter Five: Issues and Trends

• Table 5-1: Competitive Strategies of Biotech Companies

Chapter Six: Total Market Size and Forecast

• Table 6-1: The Total Market for Cancer Immunomodulators 2001-2008
• Figure 6-1: The Total Market for Cancer Immunomodulators 2001-2008
• Table 6-2: The Market for Cancer Immunomodulators by AvailabilityCurrent vs Emerging 2001-2008
• Figure 6-2: Cancer Immunomodulator Market Distribution of Revenues by Availability Current vs Emerging 2001-2008
• Figure 6-3: Distribution of Cancer Immunomodulators Available or inDevelopment by Cancer Type 2003
• Figure 6-4: Number of Products in Development by Phase and Cancer Type

 

Other users found this report page using the following search terms: immunotherapy interleukin cancer vaccine immunomodulators cancer immunomodulator therapy market treatment emerging products introduction size

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.